These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10565222)

  • 21. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in complete response as consolidation therapy, second report].
    Yamane T; Hirose A; Nakajima Y; Nakane T; Koh H; Takeoka Y; Nakamae M; Yamamura R; Nakamae H; Nakao Y; Mugitani A; Yagi T; Teshima H; Hino M
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):193-8. PubMed ID: 16484855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
    Demirer T; Ayli M; Fen T; Ozcan M; Arat M; Buyukberber S; Arslan O; Gurman G; Akan H; Ilhan O
    Bone Marrow Transplant; 2004 Nov; 34(9):781-6. PubMed ID: 15354206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapy of highly malignant non-Hodgkin lymphoma with high-dose chemotherapy and stem cell transplantation].
    Schmitz N
    Praxis (Bern 1994); 1998 Jun; 87(25-26):863-8. PubMed ID: 9702088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
    Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
    van Besien K; Rodriguez A; Tomany S; Younes A; Donato M; Sarris A; Giralt S; Mehra R; Andersson B; Gajewski J; Champlin R; Cabanillas F
    Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology.
    Won SC; Han JW; Kwon SY; Shin HY; Ahn HS; Hwang TJ; Yang WI; Lyu CJ
    Ann Hematol; 2006 Nov; 85(11):787-94. PubMed ID: 16932891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Successful double peripheral blood stem cell transplantation for patient with malignant lymphoma of primary induction failure].
    Fujii H; Nakagawa H; Nakao M; Sonoda Y; Tanimukai S
    Rinsho Ketsueki; 1998 May; 39(5):369-73. PubMed ID: 9637887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Autologous peripheral blood stem cell transplantation for Japanese multiple myeloma patients: results of a feasibility study].
    Nakamura Y; Sakamaki H; Mukai H; Kojima H; Tomiyama J; Mori S; Hiruma K; Nakamura N; Toyota S; Hamaguchi H; Dans K; Mitani K; Saito K
    Rinsho Ketsueki; 2004 Jul; 45(7):524-9. PubMed ID: 15359911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
    Wójcik B; Kowalczyk JR; Chybicka A; Wachowiak J; Drabko K; Zaucha-Prazmo A; Choma M; Gorczyńska E; Toporski J; Turkiewicz D; Kałwak K; Pieczonka A; Boruczkowski D
    Przegl Lek; 2004; 61 Suppl 2():53-6. PubMed ID: 15686047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
    Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
    Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.
    Stein RS; Greer JP; Goodman S; Brandt SJ; Morgan DS; Macon WR; McCurley TL; Wolff SN
    Bone Marrow Transplant; 2000 Feb; 25(3):257-62. PubMed ID: 10673696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma.
    Pavone V; Gaudio F; Guarini A; Perrone T; Zonno A; Curci P; Liso V
    Bone Marrow Transplant; 2002 Feb; 29(4):285-90. PubMed ID: 11896424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
    Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
    Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution.
    Magagnoli M; Castagna L; Balzarotti M; Sarina B; Timofeeva I; Bertuzzi A; Compasso S; Nozza A; Siracusano L; Santoro A
    Am J Hematol; 2003 Aug; 73(4):267-72. PubMed ID: 12879431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.